Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 6/20 | 0.44 |
| ▸ | CTSK | P43235 | 6/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269301 | 0.86 | CTSS (0.51) | TACR1KLK5CTSSCTSKSCN9A | |
| SCHEMBL269302 | 0.86 | CTSS (0.51) | TACR1KLK5CTSSCTSKSCN9A | |
| SCHEMBL30825582 | 0.85 | TACR1 (0.49) | TACR1KLK5CTSSCTSKSCN9A | |
| SCHEMBL30825581 | 0.84 | TACR1 (0.48) | TACR1KLK5CTSSCTSKSCN9A | |
| SCHEMBL31494602 | 0.84 | CTSS (0.51) | TACR1KLK5CTSSCTSKSCN9A | |
| SCHEMBL6832286 | 0.81 | AAK1 (0.45) | TACR1KLK5CTSSCTSKCACNA1B | |
| SCHEMBL3771926 | 0.81 | GSTP1 (0.52) | TACR1KLK5CTSSCTSKSCN9A | |
| SCHEMBL29675128 | 0.79 | CTSS (0.51) | TACR1KLK5CTSSCTSKCTSL | |
| SCHEMBL6832287 | 0.79 | TACR1 (0.39) | TACR1KLK5CTSSCTSKSCN9A | |
| SCHEMBL25382593 | 0.78 | CTSS (0.67) | KLK5CTSSCTSKACENOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | TACR1 3020/4885KLK5 1949/4885CTSS 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.